Halozyme Therapeutics PEG Ratio

Halozyme Therapeutics posts a PEG ratio of 81.48. That is above the Healthcare sector average of 3.22. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Healthcare stocks, a PEG ratio near 3.22 is typical. Halozyme Therapeutics's 81.48 is higher that level. That is roughly 2428.5% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Halozyme Therapeutics's PEG ratio of 81.48 comes from dividing a price-based measure by a related financial statistic. Changes can come from the stock price moving, the underlying fundamental shifting, or both. Track both the level and the trend — a rising multiple on falling fundamentals is a different story than a rising multiple on rising earnings.

Context for HALO's PEG ratio usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 3.22), and (3) consistency with growth and profitability. This page covers the first two; Halozyme Therapeutics's other metric pages and overview cover the third.

Judging Halozyme Therapeutics against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in PEG ratio easier to interpret. Start with 81.48 here, then scan peer and history charts to see if the gap is persistent.